Ryan M Rivosecchi1, Sandra L Kane-Gill2, Jeffrey Garavaglia3, Adam MacLasco4, Heather Johnson2. 1. Department of Pharmacy, UPMC Presbyterian Hospital, Pittsburgh, PA, USA. 2. School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA. 3. West Virginia University Hospitals, Morgantown, WV, USA. 4. Virginia Commonwealth University Medical Center, Richmond, VA, USA.
Abstract
OBJECTIVES: The goal of this study was to evaluate the effectiveness of intravenous (IV) vitamin K in cirrhosis. METHODS: This was a retrospective study of cirrhotic patients, not on anticoagulation, with administration of IV vitamin K and a baseline INR > 1.5. The primary outcome was the effectiveness of therapy defined by a 30% decrease in INR or a reduction in INR to an absolute value of ≤1.5. KEY FINDINGS: A total of 96 patients were included in the cohort. There was an average decrease in INR of 0.31; however, 60 patients (62.3%) failed to achieve at least a 10% decrease. Sixteen patients (16.7%) met the primary effectiveness endpoint. CONCLUSIONS: The use of IV vitamin K to correct coagulopathy of cirrhosis may not be beneficial.
OBJECTIVES: The goal of this study was to evaluate the effectiveness of intravenous (IV) vitamin K in cirrhosis. METHODS: This was a retrospective study of cirrhotic patients, not on anticoagulation, with administration of IV vitamin K and a baseline INR > 1.5. The primary outcome was the effectiveness of therapy defined by a 30% decrease in INR or a reduction in INR to an absolute value of ≤1.5. KEY FINDINGS: A total of 96 patients were included in the cohort. There was an average decrease in INR of 0.31; however, 60 patients (62.3%) failed to achieve at least a 10% decrease. Sixteen patients (16.7%) met the primary effectiveness endpoint. CONCLUSIONS: The use of IV vitamin K to correct coagulopathy of cirrhosis may not be beneficial.
Authors: Khalid Al Sulaiman; Mashael Al Mutairi; Omar Al Harbi; Alanoud Al Duraihim; Sara Aldosary; Haifa Al Khalil; Abdulrahman Al Shaya; Shmeylan Al Harbi; Nouf Alotaibi; Kholoud Al Aamer; Ramesh Vishwakarma; Mohammed Al Asiri; Ohoud Aljuhani; Abdulmalik Al Katheri; Abdulkareem M Al Bekairy Journal: Clin Appl Thromb Hemost Date: 2021 Jan-Dec Impact factor: 2.389